Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.

Chien AJ, Moasser MM.

Semin Oncol. 2008 Apr;35(2 Suppl 2):S1-S14; quiz S39. doi: 10.1053/j.seminoncol.2008.02.010. Review.

PMID:
18410794
2.

Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.

Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C.

Cancer Treat Rev. 2012 Nov;38(7):890-903. doi: 10.1016/j.ctrv.2012.02.011. Epub 2012 Mar 31. Review.

PMID:
22465195
3.

Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.

Tan MH, De S, Bebek G, Orloff MS, Wesolowski R, Downs-Kelly E, Budd GT, Stark GR, Eng C.

Breast Cancer Res Treat. 2012 Feb;131(3):849-58. doi: 10.1007/s10549-011-1500-8. Epub 2011 Apr 9.

4.

Drug transporters in breast cancer: response to anthracyclines and taxanes.

Kümler I, Stenvang J, Moreira J, Brünner N, Nielsen DL.

Expert Rev Anticancer Ther. 2015;15(9):1075-92. doi: 10.1586/14737140.2015.1067610. Review.

PMID:
26313418
5.

Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.

Fojo T, Menefee M.

Ann Oncol. 2007 Jul;18 Suppl 5:v3-8. Review.

PMID:
17656560
6.

Tubulin interacting agents: novel taxanes and epothilones.

Agrawal NR, Ganapathi R, Mekhail T.

Curr Oncol Rep. 2003 Mar;5(2):89-98. Review.

PMID:
12583825
7.

Preclinical discovery of ixabepilone, a highly active antineoplastic agent.

Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G.

Cancer Chemother Pharmacol. 2008 Dec;63(1):157-66. doi: 10.1007/s00280-008-0724-8. Epub 2008 Mar 18. Review.

PMID:
18347795
8.

Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.

Moreno-Aspitia A, Perez EA.

Clin Ther. 2009 Aug;31(8):1619-40. doi: 10.1016/j.clinthera.2009.08.005. Review.

PMID:
19808124
9.

Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer.

Perez EA.

Breast Cancer Res Treat. 2009 Mar;114(2):195-201. doi: 10.1007/s10549-008-0005-6. Epub 2008 Apr 29. Review.

PMID:
18443902
10.

Ixabepilone: a new microtubule-targeting agent for breast cancer.

Higa GM, Abraham J.

Expert Rev Anticancer Ther. 2008 May;8(5):671-81. doi: 10.1586/14737140.8.5.671. Review.

PMID:
18471040
11.

Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.

Rivera E.

Am J Clin Oncol. 2010 Apr;33(2):176-85. doi: 10.1097/COC.0b013e3181931049. Review.

PMID:
19675449
12.

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.

Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P.

Cancer Res. 2011 Sep 15;71(18):6019-29. doi: 10.1158/0008-5472.CAN-11-1417. Epub 2011 Jul 28.

13.

Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR).

Lee JJ, Swain SM.

Semin Oncol. 2005 Dec;32(6 Suppl 7):S22-6. Review.

PMID:
16360719
14.

Ixabepilone for the treatment of breast cancer.

Alvarez RH, Valero V, Hortobagyi GN.

Ann Med. 2011;43(6):477-86. doi: 10.3109/07853890.2011.579151. Epub 2011 May 17. Review.

PMID:
21585248
15.

Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer.

Wang S, Qiu J, Shi Z, Wang Y, Chen M.

Biotechnol Adv. 2015 Jan-Feb;33(1):224-41. doi: 10.1016/j.biotechadv.2014.10.011. Epub 2014 Oct 31. Review.

PMID:
25447422
16.

[A case of liver metastasis successfully treated with S-1 monotherapy in the patient with recurrent breast cancer].

Nishihara K, Mitsuyama S.

Gan To Kagaku Ryoho. 2006 Jan;33(1):129-32. Japanese.

PMID:
16410713
17.

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.

Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T.

Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2904-9.

18.

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.

Perez EA.

Mol Cancer Ther. 2009 Aug;8(8):2086-95. doi: 10.1158/1535-7163.MCT-09-0366. Epub 2009 Aug 11. Review. Erratum in: Mol Cancer Ther. 2012 Jun;11(6):1381.

19.

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.

Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, Le Cesne A, Spielmann M.

Cancer. 2001 Nov 1;92(9):2267-72.

PMID:
11745280
20.

CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.

Pabla N, Sparreboom A.

Clin Cancer Res. 2015 Mar 15;21(6):1237-9. doi: 10.1158/1078-0432.CCR-14-2551.

Supplemental Content

Support Center